Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Trevena Inc (TRVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,513
  • Shares Outstanding, K 92,354
  • Annual Sales, $ 5,730 K
  • Annual Income, $ -30,780 K
  • 60-Month Beta 2.62
  • Price/Sales 17.88
  • Price/Cash Flow N/A
  • Price/Book 2.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.99 +14.14%
on 06/12/19
1.36 -16.91%
on 05/20/19
-0.22 (-16.30%)
since 05/17/19
3-Month
0.99 +14.14%
on 06/12/19
2.00 -43.50%
on 03/20/19
-0.75 (-39.89%)
since 03/19/19
52-Week
0.38 +197.37%
on 12/24/18
3.58 -68.44%
on 10/03/18
-0.56 (-33.14%)
since 06/19/18

Most Recent Stories

More News
Trevena: 1Q Earnings Snapshot

CHESTERBROOK, Pa. (AP) _ Trevena Inc. (TRVN) on Friday reported a loss of $5.2 million in its first quarter.

TRVN : 1.13 (+1.80%)
Trevena Reports First Quarter 2019 Results

-- Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine --

TRVN : 1.13 (+1.80%)
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?

During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.

TRVN : 1.13 (+1.80%)
INCY : 84.87 (+0.70%)
GILD : 68.26 (+0.09%)
ADRO : 1.91 (-1.55%)
Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study

Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.

TRVN : 1.13 (+1.80%)
PDLI : 3.02 (+0.67%)
MRUS : 15.13 (+9.24%)
MNK : 9.39 (+0.43%)
AMAG Pharmaceuticals Appoints New Members to Board of Directors

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the election of two new members to its Board of Directors--Anne Phillips, M.D., senior vice president, clinical development, medical and regulatory...

TRVN : 1.13 (+1.80%)
UL : 62.49 (+0.24%)
AMAG : 8.78 (-4.04%)
TRHC : 52.25 (+6.33%)
Report: Developing Opportunities within 22nd Century Group, Darling Ingredients, Silvercorp Metals, Trevena, Star Bulk Carriers, and AngioDynamics -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of 22nd Century Group, Inc (NYSE:XXII),...

TRVN : 1.13 (+1.80%)
DAR : 20.14 (+1.61%)
SBLK : 8.67 (+3.58%)
XXII : 2.06 (+1.48%)
SVM : 2.40 (+0.42%)
ANGO : 19.61 (+0.15%)
Trevena (TRVN) Gains As Market Dips: What You Should Know

Trevena (TRVN) closed at $1.70 in the latest trading session, marking a +1.19% move from the prior day.

TRVN : 1.13 (+1.80%)
Will Trevena Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Trevena.

TRVN : 1.13 (+1.80%)
Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

TRVN : 1.13 (+1.80%)
CELG : 97.83 (+0.70%)
PBYI : 14.05 (+0.29%)
RHHBY : 35.2300 (+1.12%)
Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?

Is (TRVN) Outperforming Other Medical Stocks This Year?

TRVN : 1.13 (+1.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Trade TRVN with:

Business Summary

Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of...

See More

Key Turning Points

2nd Resistance Point 1.18
1st Resistance Point 1.16
Last Price 1.13
1st Support Level 1.10
2nd Support Level 1.06

See More

52-Week High 3.58
Fibonacci 61.8% 2.36
Fibonacci 50% 1.98
Fibonacci 38.2% 1.60
Last Price 1.13
52-Week Low 0.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar